{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:43:31Z","timestamp":1794951811468,"version":"4.9.1"},"reference-count":281,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/14712598.2024.2436094","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:06:07Z","timestamp":1733979967000},"page":"93-118","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":74,"title":["Strategies for extending the half-life of biotherapeutics: successes and complications"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-0630","authenticated-orcid":false,"given":"Uli","family":"Binder","sequence":"first","affiliation":[{"name":"XL-protein GmbH, Freising, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-498X","authenticated-orcid":false,"given":"Arne","family":"Skerra","sequence":"additional","affiliation":[{"name":"Lehrstuhl f\u00fcr Biologische Chemie, Technische Universit\u00e4t M\u00fcnchen, Freising, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527807796.ch1"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20125"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527609628.ch1"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527644827.ch2"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.02.010"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24793"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830180221"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.10.037"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)40292-4"},{"issue":"3","key":"e_1_3_5_14_1","first-page":"649","article-title":"Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol","volume":"46","author":"Davis S","year":"1981","unstructured":"Davis S, Abuchowski A, Park YK, et al. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol. 1981 Dec;46(3):649\u2013652.","journal-title":"Clin Exp Immunol"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10600"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1515\/bchm2.1954.297.1.149"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1515\/znb-1955-0106"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(17)40291-2"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199333011-00009"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.12.1977"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7643-8679-5_12"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1997.2128"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc000082g"},{"issue":"2","key":"e_1_3_5_24_1","first-page":"121","article-title":"The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis","volume":"10","author":"Alavian SM","year":"2010","unstructured":"Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010 Spring;10(2):121\u2013131.","journal-title":"Hepat Mon"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2015.11.015"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100387108"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000190"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312474726"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318791801"},{"key":"e_1_3_5_30_1","unstructured":"Gegg C Kinstler O inventors; Amgen assignee. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility. United States patent US6420339B1. 2002 Jul 16."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje-09-0422"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0203"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250802413856"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae693"},{"key":"e_1_3_5_35_1","unstructured":"Frey H Matthes R Dreier P et al.; inventors; Johannes-Gutenberg-Universitaet Mainz assignee. Poly(ethylene glycol) having Cl to C3-alkyloxy methyl side chains bioconjugates thereof process for its preparation and its use. International patent publication WO2022238532A1. 2022 Nov 17."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc500523t"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.014910"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21278"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2019.09.023"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00428"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.06.040"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.08.276"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22739"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.720969"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12760"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1039\/d3nh00198a"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114079"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2021.715844"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.3291"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00825-x"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.0c01627"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c09232"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.8b00237"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.8b00548"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872211312666180717164758"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.978282"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2014.03.010"},{"issue":"90","key":"e_1_3_5_58_1","first-page":"6","article-title":"Chonylation: a new drug delivery technology for improving the therapeutic efficacy of proteins and peptides utilizing naturally-occurring sugar polymer chondroitin (CH) as an alternative to polyethylene glycol","volume":"6","author":"Takatsu Y","year":"2017","unstructured":"Takatsu Y. Chonylation: a new drug delivery technology for improving the therapeutic efficacy of proteins and peptides utilizing naturally-occurring sugar polymer chondroitin (CH) as an alternative to polyethylene glycol. J Pharm Drug Deliv Res. 2017;6(90):6.","journal-title":"J Pharm Drug Deliv Res"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2012.11.090"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzt023"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1588"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.03.016"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-017-0078"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.5b01031"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2009.12.002"},{"key":"e_1_3_5_67_1","unstructured":"Leung DW Bergman PA Lofquist A et al. inventors; Cell therapeutics assignee. Recombinant production of polyanionic polymers and uses thereof. United States patent US20020169125A1. 2008 Nov 14."},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzm020"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.04.019"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-409547-2.14240-4"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123871"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201802452"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120606"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.0c00286"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ces.2005.04.040"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01450"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/1574-6976.12056"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-016-9665-3"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.7b00492"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.8b00467"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b00059"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwx072"},{"key":"e_1_3_5_83_1","volume-title":"Poster, International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting","author":"Behrens C","year":"2015","unstructured":"Behrens C, Buchardt J, Broberg ML, et al. Heparosan glyco-conjugates of rFVIII and rFIX show prolonged circulating half-life in haemophilia mouse models. In: Poster, International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting; Toronto, Canada; 2015."},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.17221\/1930-vetmed"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s3118"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150107151906"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.06.033"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2016.07.018"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800911795655976"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4838(91)90085-e"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14837"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-4838(97)00056-3"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.13.153"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13878"},{"key":"e_1_3_5_95_1","unstructured":"Xenetic Biosciences announces positive phase 1 clinical results for PSA-oxyntomodulin for the treatment of type II diabetes and obesity. 2014 [cited 2024 Oct 21]. Available from: https:\/\/www.xeneticbio.com\/news-media\/press-releases\/detail\/11\/xenetic-biosciences-announces-positive-phase-1-clinical"},{"key":"e_1_3_5_96_1","unstructured":"Genetic Engineering & Biotechnology News. Shire hemophilia candidate using Xenetic platform falls short in trial. Mary Ann Liebert; 2017 [cited 2024 Oct 21]. Available from: https:\/\/www.genengnews.com\/news\/shire-hemophilia-candidate-using-xenetic-platform-falls-short-in-trial"},{"key":"e_1_3_5_97_1","unstructured":"Accesswire. Xenetic Biosciences Inc. announces partner\u2019s filing of registration dossier in Russia for epolong product candidate that utilizes Xenetic\u2019s PolyXen(R) platform technology. 2021 [cited 2024 Oct 21]. Available from: https:\/\/www.accesswire.com\/629823\/xenetic-biosciences-inc-announces-partners-filing-of-registration-dossier-in-russia-for-epolong-product-candidate-that-utilizes-xenetics-polyxen-r-platform-technology"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm91030032"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-151-2_2"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527644827.ch7"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.09.031"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24253"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.430"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(01)00200-8"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00622"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1746"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V10112392"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0133-6"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.6.1461"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0026"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4304"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.2217\/whe.10.56"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1431"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3547"},{"key":"e_1_3_5_115_1","first-page":"e989","article-title":"Enhancing the longevity and in vivo potency of therapeutic proteins: the power of CTP","volume":"2","author":"Calo D","year":"2015","unstructured":"Calo D, Hart G, Hoffman M, et al. Enhancing the longevity and in vivo potency of therapeutic proteins: the power of CTP. Precis Med. 2015;2:e989.","journal-title":"Precis Med"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13428"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27103272"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02674.x"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-015-0205-1"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.6.2025.406k19_2025_2032"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/bip.23069"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.10.010"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-022-01948-5"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2017.06.004"},{"key":"e_1_3_5_125_1","first-page":"30","article-title":"High-yield production of PASylated human growth hormone using secretory E. coli technology","volume":"11","author":"Di Cesare S","year":"2013","unstructured":"Di Cesare S, Binder U, Maier T, et al. High-yield production of PASylated human growth hormone using secretory E. coli technology. BioProcess Int. 2013;11:30\u201338.","journal-title":"BioProcess Int"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070967"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1626652"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007246"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081927"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-020-00638-7"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c01066"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2014.985522"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.11.003"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)49941-8"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.602474"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c04071"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86641-0"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0765-z"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2023.153526"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20811-5"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.06.030"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.3c00464"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010124"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp5007147"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10930-017-9699-9"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2019.100501"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202305551"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2022.102622"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1519"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115473"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.90376"},{"key":"e_1_3_5_152_1","unstructured":"GlobeNewswire. Akari Therapeutics and Peak Bio announce portfolio prioritization plan for combined go-forward merger entity Boston and Pleasanton. 2024 [cited 2024 Oct 21]. Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2024\/05\/01\/2873214\/0\/en\/Akari-Therapeutics-and-Peak-Bio-Announce-Portfolio-Prioritization-Plan-for-Combined-Go-Forward-Merger-Entity.html"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.04.051"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.10.038"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23229"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1437"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3279"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz149"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284498"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001292"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009197"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101164"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00536-9"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13499"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2024.05.013"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.041"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.07.022"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471140864.ps0611s61"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22952"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(13)60645-2"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.06.269"},{"key":"e_1_3_5_172_1","first-page":"6504","article-title":"Weekly subcutaneous doses of glymera (PB1023), a novel GLP-1 analogue reduces glucose exposure dose dependently","volume":"61","author":"Christiansen M","year":"2012","unstructured":"Christiansen M. Weekly subcutaneous doses of glymera (PB1023), a novel GLP-1 analogue reduces glucose exposure dose dependently. Am Diabetes Assoc. 2012;61:6504.","journal-title":"Am Diabetes Assoc"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13025"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1161\/res.129.suppl_1.P371"},{"key":"e_1_3_5_175_1","unstructured":"Immunoforge. Main pipelines. 2024 [cited 2024 Aug 15]. Available from: https:\/\/www.immunoforge.com\/en\/m21.php?slide=1"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.11.012"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.1039\/d2sc03519g"},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101674"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.2c00176"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202004995"},{"key":"e_1_3_5_181_1","doi-asserted-by":"publisher","DOI":"10.1038\/337525a0"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2123299"},{"key":"e_1_3_5_183_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00580"},{"key":"e_1_3_5_184_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1"},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.6.1483"},{"key":"e_1_3_5_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88269-7"},{"key":"e_1_3_5_187_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01582-x"},{"key":"e_1_3_5_188_1","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s1379"},{"key":"e_1_3_5_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(03)80164-9"},{"key":"e_1_3_5_190_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1923366"},{"key":"e_1_3_5_191_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903296"},{"key":"e_1_3_5_192_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1802135"},{"key":"e_1_3_5_193_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2009.10.011"},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179604"},{"key":"e_1_3_5_195_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601"},{"issue":"11","key":"e_1_3_5_196_1","first-page":"2204","article-title":"Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity","volume":"34","author":"Davis PM","year":"2007","unstructured":"Davis PM, Abraham R, Xu L, et al. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol. 2007 Nov;34(11):2204\u20132210.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_197_1","doi-asserted-by":"publisher","DOI":"10.15326\/jcopdf.2023.0469"},{"key":"e_1_3_5_198_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm811"},{"key":"e_1_3_5_199_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02058-9"},{"key":"e_1_3_5_200_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"e_1_3_5_201_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.160"},{"key":"e_1_3_5_202_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2810"},{"key":"e_1_3_5_203_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1080"},{"key":"e_1_3_5_204_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.002"},{"key":"e_1_3_5_205_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060913"},{"key":"e_1_3_5_206_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-012-0500-5"},{"key":"e_1_3_5_207_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.02.311"},{"key":"e_1_3_5_208_1","unstructured":"Business Wire. Genexine and KGbio received the first market approval for novel long-acting erythropoietin efepoetin alfa from the Indonesian food and drug authority (BPOM). 2023 [cited 2024 Oct 21]. Available from: https:\/\/www.businesswire.com\/news\/home\/20231022313600\/en\/Genexine-and-KGbio-received-the-first-market-approval-for-novel-long-acting-Erythropoietin-Efepoetin-alfa-from-The-Indonesian-Food-and-Drug-Authority-BPOM"},{"key":"e_1_3_5_209_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3227"},{"key":"e_1_3_5_210_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21024"},{"key":"e_1_3_5_211_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2741"},{"key":"e_1_3_5_212_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.02.005"},{"key":"e_1_3_5_213_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.951322"},{"key":"e_1_3_5_214_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S80814"},{"key":"e_1_3_5_215_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01866-9"},{"key":"e_1_3_5_216_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200620030-00002"},{"key":"e_1_3_5_217_1","doi-asserted-by":"publisher","DOI":"10.3109\/07388551.2013.834293"},{"key":"e_1_3_5_218_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00447-y"},{"key":"e_1_3_5_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2014.11.001"},{"key":"e_1_3_5_220_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14424"},{"key":"e_1_3_5_221_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1012816"},{"key":"e_1_3_5_222_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1870"},{"key":"e_1_3_5_223_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-013-0015-2"},{"key":"e_1_3_5_224_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172398299"},{"key":"e_1_3_5_225_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"e_1_3_5_226_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b00345"},{"key":"e_1_3_5_227_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002566"},{"key":"e_1_3_5_228_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2008.05.010"},{"key":"e_1_3_5_229_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.07.075"},{"key":"e_1_3_5_230_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/481520"},{"key":"e_1_3_5_231_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi052628y"},{"key":"e_1_3_5_232_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540"},{"key":"e_1_3_5_233_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.5.1904"},{"key":"e_1_3_5_234_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0228-2"},{"key":"e_1_3_5_235_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3795-1"},{"key":"e_1_3_5_236_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvae006"},{"key":"e_1_3_5_237_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"e_1_3_5_238_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01260-9"},{"key":"e_1_3_5_239_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_3_5_240_1","unstructured":"Monaco K. Withdrawn diabetes drug worked in secondary CV prevention: MedPage Today. 2018 [cited 2024 Oct 21]. Available from: https:\/\/www.medpagetoday.com\/cardiology\/prevention\/75501"},{"key":"e_1_3_5_241_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S236788"},{"key":"e_1_3_5_242_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041071"},{"key":"e_1_3_5_243_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-04-0255"},{"key":"e_1_3_5_244_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1364"},{"key":"e_1_3_5_245_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2007.04.016"},{"key":"e_1_3_5_246_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.081828"},{"key":"e_1_3_5_247_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1008345"},{"key":"e_1_3_5_248_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.12.019"},{"key":"e_1_3_5_249_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.463000"},{"key":"e_1_3_5_250_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0152"},{"key":"e_1_3_5_251_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1607"},{"key":"e_1_3_5_252_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.07.023"},{"key":"e_1_3_5_253_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0580"},{"key":"e_1_3_5_254_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500810s"},{"key":"e_1_3_5_255_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2284685"},{"key":"e_1_3_5_256_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00226"},{"key":"e_1_3_5_257_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S54953"},{"key":"e_1_3_5_258_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.2006.2.3.277"},{"key":"e_1_3_5_259_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2024.2324918"},{"key":"e_1_3_5_260_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S336285"},{"key":"e_1_3_5_261_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051286"},{"key":"e_1_3_5_262_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp500519s"},{"key":"e_1_3_5_263_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z"},{"key":"e_1_3_5_264_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13409"},{"key":"e_1_3_5_265_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020"},{"key":"e_1_3_5_266_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106030"},{"key":"e_1_3_5_267_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.0c00019"},{"key":"e_1_3_5_268_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzn028"},{"issue":"1","key":"e_1_3_5_269_1","first-page":"534","article-title":"Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor","volume":"277","author":"Makrides SC","year":"1996","unstructured":"Makrides SC, Nygren PA, Andrews B, et al. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther. 1996 Apr;277(1):534\u2013542.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_5_270_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzm061"},{"key":"e_1_3_5_271_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.246652"},{"key":"e_1_3_5_272_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0278-1"},{"key":"e_1_3_5_273_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad186"},{"key":"e_1_3_5_274_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzm067"},{"key":"e_1_3_5_275_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.187"},{"key":"e_1_3_5_276_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0514-9"},{"key":"e_1_3_5_277_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2231344"},{"key":"e_1_3_5_278_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.07.011"},{"key":"e_1_3_5_279_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173353"},{"key":"e_1_3_5_280_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2022.170760"},{"key":"e_1_3_5_281_1","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0290011"},{"key":"e_1_3_5_282_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-323-3_3"},{"key":"e_1_3_5_283_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-019-0345-9"},{"key":"e_1_3_5_284_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.204701"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2436094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:02:43Z","timestamp":1735776163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2436094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":281,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/14712598.2024.2436094"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2436094","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}